The size of the In-Vitro fertilization (IVF) market in Europe is expected to reach USD 1.75 billion by 2025 from USD 0.85 billion in 2020, growing at a CAGR of 15.4% during the forecast period.
The in vitro fertilization market in Europe is expected to experience steady and continuous growth, mainly in France, Germany, and the United Kingdom. This is due to supporting regulations such as the UK Human Fertilization and Embryo Authority (HFEA), which tightly regulates the operation of in vitro fertilization treatments and research in the UK. The subsidy of IVF treatments in Germany due to the falling birth rate of around 2.21 children/women is an essential factor in the growth of this market. Besides, the National Health Plan (PSN) covers approximately 50% of the total cost of treatment. It supports three cycles of in vitro fertilization, which is expected to boost the in vitro fertilization market, especially in Germany.
The main factors limiting this market growth are costs incurred and strict government regulations. A patient may need to have multiple pregnancy cycles due to the lower success rate of IVF procedures, which increases the total cost. The average cost of this procedure is approximately $ 15,125 to $ 25,300, which is often a significant barrier to adopting the technique. Besides, ethical considerations and lack of reimbursement are other challenges that are hampering the growth of the market.
This research report on the Europe In-vitro Fertilization Market has been segmented and sub-segmented into the following categories:
Regional Analysis:
The European region enjoys an excellent reputation in the global IVF market, as it was the first region to introduce the IVF procedure. Besides, Europe has been one of the champions of the legalization of trip rental in vitro fertilization or the mitochondrial transfer technique. The Spanish market is expected to accelerate with the highest CAGR by the end of 2025.
However, in terms of revenue, the UK IVF market is expected to dominate this region. The in vitro fertilization market in Europe is expected to experience steady and continuous growth, mainly in France, Germany, and the United Kingdom. This is due to supporting regulations such as the UK Human Fertilization and Embryo Authority (HFEA), which tightly regulates the operation of in vitro fertilization treatments and research in the UK. France accounted for the highest number of IVF cycles per year in 2020, while the UK is expected to grow at the highest CAGR in terms of volume and value. Spain is expected to be the main contributor to the region's overall revenues, with a CAGR of 7.2.1%, due to the increase in fertility tourism and the high success rates of the treatments provided. The UK is expected to have the highest growth rate of the European IVF market, with a CAGR of 8.1%, in terms of revenue. In 2020, the EU5 (Germany, France, United Kingdom, Spain, and Italy) collectively accounted for around three-fifths of the market volume.
Companies playing a dominant role in the European in-Vitro fertilization Market profiled in this report are Cooper Surgical, Inc. (U.S.), Vitrolife AB (Sweden), Cook Medical, Inc. (U.S.), Irvine Scientific (U.S.), Thermo Fisher Scientific, Inc. (U.S.), EMD Serono, Inc. (U.S.), Genea Limited (Australia), ESCO Micro Pte. Limited (Singapore), IVFtech ApS (Denmark), and The Baker Company, Inc. (U.S.).
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5.1 Introduction
5.2 Reagents and Media
5.2.1 Introduction
5.2.2 Embryo Culture Media
5.2.3 Cryopreservation Media 5.2.2.1 Autologous Cell-Based Products
5.2.4 Sperm Processing Media 5.2.2.2 Allogeneic Cell-Based Products
5.2.5 Ovum Processing Media
5.3 Instruments
5.3.1 Introduction
5.3.2 Imaging Systems
5.3.3 Sperm Separation Systems
5.3.4 Ovum Aspiration Pumps
5.3.5 Incubators
5.3.6 Micromanipulator Systems
5.3.7 Cryosystems
5.3.8 Other Instruments (Gas Analyzers, Laser Systems, Accessories)
5.4 Technology
5.3.1 Introduction
5.3.2 Intra-Cytoplasmic Sperm Injection (ICSI)
5.3.3 Pre-Implantation Genetic Diagnosis (PGD)
5.3.4 Frozen Embryo Transfer/Replacement (FET/FER)
5.3.5 Other Technologies
5.5 End Users
5.4.1 Introduction
5.4.2 Fertility and Surgical Centers
5.4.3 Hospitals and Research Laboratories
5.4.4 Cryobanks
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.1 CooperSurgical, Inc. (U.S.)
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Cook Medical, Inc. (U.S.)
8.3 Irvine Scientific (U.S.)
8.4 Vitrolife AB (Sweden)
8.5 Thermo Fisher Scientific, Inc. (U.S.)
8.6 EMD Serono, Inc. (U.S.)
8.7 Genea Limited (Australia)
8.8 ESCO Micro Pte. Limited (Singapore)
8.9 IVFtech ApS (Denmark)
8.10 The Baker Company, Inc. (U.S.)
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Apr 2021
